期刊
JOURNAL OF ALZHEIMERS DISEASE
卷 64, 期 -, 页码 S213-S227出版社
IOS PRESS
DOI: 10.3233/JAD-179943
关键词
Amyloid; biomarkers; clinical trials; cognition; diagnosis; lifestyle; neuronal injury; preclinical Alzheimer's disease; prognosis; vascular risk
Increasing interest in clinical trials and clinical research settings to identify Alzheimer's disease (AD) in the earliest stages of the disease has led to the concept of preclinical AD. Individuals with preclinical AD have AD pathology without clinical symptoms yet. Accumulating evidence has shown that biomarkers can identify preclinical AD and that preclinical AD is associated with a poor clinical outcome. Little is known yet about the role of vascular and lifestyle risk factors in the development of preclinical AD. In order to better understand preclinical AD pathology and clinical progression rates, there is a need to refine the concept of preclinical AD. This will be of great value for advancements in future research, clinical trials, and eventually clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据